01 Growth of Pediatric-Focused HIV Clinical TrialsA key trend in the HIV clinical trials market is the increasing emphasis on pediatric populations. For example, ViiV Healthcare initiated the ODYSSEY trial to evaluate optimized antiretroviral regimens in children living with HIV. Focusing on pediatric studies addresses unmet treatment needs, ensures age-appropriate formulations, and expands the market by supporting safer, more effective therapies for younger patients globally.
02 Rise of Decentralized and Virtual Clinical TrialsMajor HIV clinical trial sponsors, including Merck & Co. Inc. and Janssen Pharmaceuticals, are adopting decentralized and virtual trial models to improve patient recruitment and retention. By using telemedicine, remote monitoring, and digital data collection, these trials reduce geographic barriers and enhance participant engagement. This trend enables faster study execution and broader population access, positioning companies to strengthen their competitive presence in the global market.
01 Growing Investment in the Development of Long-Acting Antiretroviral TherapiesThe surge in development of antiretroviral therapies is a key driver for market growth. The increasing prevalence of HIV and the need for improved patient adherence accelerated the development of long-acting injectable therapies. In 2024, ViiV Healthcare advanced its cabotegravir-based regimen through multiple global Phase III trials, while Gilead Sciences expanded its long-acting portfolio with novel investigational agents. These developments demonstrate that companies are prioritizing these therapies to reduce dosing frequency and address unmet clinical needs, thereby driving the growth of the HIV clinical trials market.
01 Limited patient recruitment and high dropout ratesRecruiting participants for long-term and multiphase studies is challenging due to geographic barriers and strict eligibility criteria. High dropout rates and difficulties in enrolling diverse populations slow trial progress, increase costs, and limit the ability of sponsors to generate robust data. Recently, a CHOICES study aimed to evaluate extended-release naltrexone (XR-NTX) for opioid use disorder in HIV positive individuals, faced barriers, including stigma associated with HIV and substance use.Thus, limited patient recruitment and high dropout rates pose a barrier to market growth and the timely development of new HIV therapies.
01 Development of Functional VaccinesDeveloping therapeutic vaccines aimed at a functional HIV cure presents a major opportunity for market growth. Current antiretroviral therapies effectively suppress HIV but cannot eradicate the virus, requiring lifelong treatment. Companies focusing on vaccines that target latent viral reservoirs address this critical unmet need.Therefore, investing in functional cure strategies allows manufacturers to develop new candidates and conduct clinical trials of these vaccine candidates.
June 2026 Gilead Sciences expanded its HIV clinical research portfolio by advancing next-generation antiviral therapies and long-acting treatment approaches through clinical trials. The company focused on developing innovative HIV prevention and treatment solutions designed to improve patient outcomes, reduce dosing frequency, and enhance treatment accessibility.
April 2026 ViiV Healthcare expanded its HIV clinical trial programs by advancing long-acting injectable therapies and novel treatment combinations. The company focused on evaluating new approaches that improve adherence, reduce treatment burden, and support long-term HIV management.
January 2026 Merck & Co. expanded its infectious disease research portfolio by advancing HIV clinical studies focused on innovative antiviral candidates, immune-based therapies, and combination treatment strategies designed to address evolving challenges in HIV care.
October 2025 Moderna expanded its HIV vaccine research initiatives by progressing clinical trial programs evaluating mRNA-based vaccine candidates designed to stimulate immune responses and support future HIV prevention strategies.